Where Crinetics Pharmaceuticals Stands With Analysts
Portfolio Pulse from Benzinga Insights
Crinetics Pharmaceuticals (NASDAQ:CRNX) has received 5 bullish analyst ratings in the last quarter, with an average price target of $43.4, implying an upside from the current price of $21.96. The average price target has increased by 5.85% over the past month.
June 08, 2023 | 9:02 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Crinetics Pharmaceuticals has 5 bullish analyst ratings with an average price target of $43.4, indicating potential upside from its current price of $21.96.
The article mentions that Crinetics Pharmaceuticals has received 5 bullish analyst ratings in the last quarter, with an average price target of $43.4, which is significantly higher than its current price of $21.96. This implies a potential upside for the stock in the short term. The average price target has also increased by 5.85% over the past month, indicating growing optimism among analysts.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100